Ajanta Pharma promoter sells 2.76% stake for about ₹1,046 cr
Ravi Agrawal Trust cut the promoter group's holding from 13% to 10.24% in open-market trades on June 9.
— 1 earlier story on Ajanta Pharma Ltd. →What's new
- Ravi Agrawal Trust sold 3.45m Ajanta Pharma shares (2.76%) on June 9 in open-market trades.
- The sale trimmed the promoter group's stake from 13% to 10.24%, though it remains the largest single promoter entity.
- Shares were sold at an undisclosed price on both the BSE and NSE.
Why this matters
A promoter entity liquidating nearly 3% of a ₹37,900 crore company in a single session is a clear signal of reduced commitment, especially after recent pledge activity. The sale removes a long-standing floor under the stock and raises questions about where the remaining 10.24% stake is headed.
What we're watching
- Any follow-on sales by other promoter group entities in the coming weeks.
- Disclosure of the sale price, which will clarify the discount, if any, to market.
- Ajanta's response and any official comment from the Agrawal family.
The full read
Ravi Agrawal Trust, the largest single entity within Ajanta Pharma's promoter group, dumped 3.45 million shares on June 9. That's 2.76% of the drugmaker's equity sold in open-market trades across the BSE and NSE. The sale is worth an estimated ₹1,046 crore at current prices for a company with a ₹37,900 crore market cap. The promoter group's total stake has now fallen from 13% to 10.24%. The price wasn't disclosed, but the scale of the transaction speaks for itself: a single promoter entity offloading nearly 3% of a mid-cap in one session, after recent pledge activity. That's not a rebalancing. It's a reduction. The open question is whether the remaining holding is stable or a target for further sales.
Questions answered
- How much did the promoter sell, and what is the stake left?
- Ravi Agrawal Trust sold 3.45 million shares, or 2.76% of the company. Its holding after the sale is 10.24%, which is still the largest single entity within the promoter group.
- Is this a forced sale or a deliberate choice?
- The filing provides no reason for the sale. The analyst rationale notes it comes after recent pledge activity, which could indicate a liquidity need, but the explicit motive is not disclosed.
- What was the sale price?
- The transactions were executed at an undisclosed price on the BSE and NSE. Without the price, it's impossible to gauge whether the shares were sold at a discount or premium to the current market rate.
- How does this sale compare to the company's size?
- Ajanta Pharma has a market capitalisation of about ₹37,900 crore. The stake sale is worth an estimated ₹1,046 crore at current prices, representing a substantial single-day liquidity event for a promoter entity.
Story so far
All notes on AJANTPHARM →- 9 Jun 2026 · 3:42 PM IST Ajanta Pharma promoter sells 2.76% stake for about ₹1,046 cr
- today Ajanta Pharma promoters just borrowed against another 2.2% of the company.